OncLive TV

S. Daniel Haldar, MD, discusses outcomes for NeoAg-Vax with or without pembrolizumab in MSS metastatic colorectal cancer.

Chad Tang, MD, discusses outcomes for metastasis-directed radiotherapy without systemic therapy in oligometastatic clear cell renal cell carcinoma.

Quoc-Dien Trinh, MD, MBA, discusses outcomes for darolutamide plus ADT in Black patients with metastatic hormone-sensitive prostate cancer.

Alireza Ghoreifi, MD, discusses the feasibility of consolidative surgery for advanced urothelial cancer receiving pembrolizumab/enfortumab vedotin.

Joseph Jacob, MD, MCR, discusses how emerging data for TAR-200 could represent a shift in the treatment paradigm for patients with high-risk non–muscle-invasive bladder cancer.

Colin P.N. Dinney, MD, discusses urinary genomic disease burden as a potential biomarker for response to cretostimogene grenadenorepvec in bladder cancer.

Mikkael A. Sekeres, MD, discusses questions that remain unanswered regarding the association between smoking and MDS development and progression.

Matthew Cortese, MD, MPH, discusses the rationale for an analysis of the immunologic activity of venetoclax in patients with chronic lymphocytic leukemia.

Benjamin Herzberg, MD, discusses unanswered questions regarding the role of KRAS inhibitors for patients with non–small cell lung cancer.

Jason A. Mouabbi, MD, discusses how ESR1 mutations can cause patients with HR-positive, HER2-negative breast cancer to develop endocrine resistance.

Neelam Desai, MD, discusses the role of a palbociclib-containing regimen in HR-positive, HER2-positive metastatic breast cancer.

Drs Mahtani, McCann, and Melody all reflect on advice they'd offer to aspiring female oncologists.

Rene Y. McNall-Knapp, MD, discusses the current treatment paradigm for pediatric and adult patients with NF1-associated PNs.

Paul E. Oberstein, MD, discusses the clinical applications of the Oncodetect test for molecular residual disease detection in patients with solid tumors.

Azka Ali, MD, discusses the use of palbociclib to overcome resistance to anti-HER2 and endocrine therapies in HER2-positive breast cancer.

Bradley McGregor, MD, highlights the outcomes of an exposure response analysis assessing the optimal dose of tivozanib in patients with RCC.

R. Lor Randall, MD, FACS, discusses whether patients with low-grade chondosarcomas should undergo intralesional curettage or en bloc resection.

Ecaterina Dumbrava, MD, discusses early findings of rezatapopt in patients with solid tumors harboring TP53 Y220C mutations.

Sairah Ahmed, MD, discusses safety data with NKTR-255 in patients with relapsed/refractory large B-cell lymphoma.

Janine Joseph, MS, MBA, discusses the current state of research and future directions for resistance training interventions in patients with multiple myeloma.

Claire Harrison, MD, FRCP, FRCPath, discusses factors informing treatment selection for patients with myelofibrosis.

Kiavasch Mohammad Nejad Farid, MD, discusses 2 planned investigations of MDC-CAR-BCMA001 in relapsed/refractory multiple myeloma and AL amyloidosis.

Hyun Woong Cho, MD, PhD, explains the rationale for assessing niraparib/bevacizumab in platinum-sensitive, recurrent ovarian cancer.

Scott Tykodi, MD, PhD, discusses data from CheckMate 214 for nivolumab plus ipilimumab vs sunitinib in favorable-risk advanced RCC.

Paolo Tarantino, MD, the clinical impact of the KATHERINE trial in reshaping the post-surgical treatment algorithm for HER2+ breast cancer care.

Alfred L. Garfall, MD, MS, discusses the rationale of the phase 2 BMT CTN 1902 trial in multiple myeloma.

Raajit Rampal, MD, discusses treatment decision-making factors, such as JAK inhibitor efficacy and signs of treatment failure, for myelofibrosis.

Douglas B. Flora, MD, LSSBB, discusses the potential utility of GPT models for improving clinical trial screening and workflows in oncology.

Andrew Ip, MD, discusses the need for real-world studies investigating the efficacy and safety of CAR T-cell therapy in patients with LBCL.

Michael R. Bishop, MD, explains the rationale for assessing the CAR T-cell therapy anito-cel in relapsed/refractory multiple myeloma.